Presymptomatic studies in genetic frontotemporal dementia

Por Rohrer, J.D., Warren, J.D., Fox, N.C., Rossor, M.N.
Publicado em 2013

Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease.

Por Fox, N. C., Freeborough, P. A., Mekkaoui, K. F., Stevens, J. M., Rossor, M. N.
Publicado em 1997

Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment

Por Schott, J.M., Bartlett, J.W., Barnes, J., Leung, K.K., Ourselin, S., Fox, N.C.
Publicado em 2010

Brain-water diffusion coefficients reflect the severity of inherited prion disease

Por Hyare, H., Wroe, S., Siddique, D., Webb, T., Fox, N. C., Stevens, J., Collinge, J., Yousry, T., Thornton, J. S.
Publicado em 2010

Measuring disease progression in frontotemporal lobar degeneration: A clinical and MRI study

Por Gordon, E., Rohrer, J. D., Kim, L. G., Omar, R., Rossor, M. N., Fox, N. C., Warren, J. D.
Publicado em 2010

Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease

Por Henley, S.M.D., Ridgway, G.R., Scahill, R.I., Klöppel, S., Tabrizi, S.J., Fox, N.C., Kassubek, J.
Publicado no AJNR Am J Neuroradiol (2010)

Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration

Por Rohrer, J D., Warren, J D., Modat, M, Ridgway, G R., Douiri, A, Rossor, M N., Ourselin, S, Fox, N C.
Publicado em 2009

Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals

Por Paterson, R W, Bartlett, J W, Blennow, K, Fox, N C, Shaw, L M, Trojanowski, J Q, Zetterberg, H, Schott, J M
Publicado em 2014

Biomarkers in dementia: clinical utility and new directions

Por Ahmed, R M, Paterson, R W, Warren, J D, Zetterberg, H, O'Brien, J T, Fox, N C, Halliday, G M, Schott, J M
Publicado no J Neurol Neurosurg Psychiatry (2014)

Hippocampal atrophy rates in Alzheimer disease: Added value over whole brain volume measures

Por Henneman, W J.P., Sluimer, J D., Barnes, J, van der Flier, W M., Sluimer, I C., Fox, N C., Scheltens, P, Vrenken, H, Barkhof, F
Publicado em 2009

Operationalizing hippocampal volume as an enrichment biomarker for amnestic MCI trials: effect of algorithm, test-retest variability and cut-point on trial cost, duration and sampl...

Por Yu, P., Sun, J., Wolz, R., Stephenson, D., Brewer, J., Fox, N.C., Cole, P.E., Jack, C.R., Hill, D.L.G., Schwarz, A.J.
Publicado em 2013

Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study

Por Hobbs, N.Z., Barnes, J., Frost, C., Henley, S.M.D., Wild, E.J., Macdonald, K., Barker, R.A., Scahill, R.I., Fox, N.C., Tabrizi, S.J.
Publicado no AJNR Am J Neuroradiol (2010)

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease

Por Henneman, W J.P., Vrenken, H, Barnes, J, Sluimer, I C., Verwey, N A., Blankenstein, M A., Klein, M, Fox, N C., Scheltens, P, Barkhof, F, van der Flier, W M.
Publicado em 2009

Conversion of amyloid positive and negative MCI to AD over 3 years: An (11)C-PIB PET study

Por Okello, A, Koivunen, J, Edison, P, Archer, H A., Turkheimer, F E., Någren, K, Bullock, R, Walker, Z, Kennedy, A, Fox, N C., Rossor, M N., Rinne, J O., Brooks, D J.
Publicado em 2009

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

Por Magdalinou, N K, Paterson, R W, Schott, J M, Fox, N C, Mummery, C, Blennow, K, Bhatia, K, Morris, H R, Giunti, P, Warner, T T, de Silva, R, Lees, A J, Zetterberg, H
Publicado no J Neurol Neurosurg Psychiatry (2015)

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology

Por Paterson, R W, Heywood, W E, Heslegrave, A J, Magdalinou, N K, Andreasson, U, Sirka, E, Bliss, E, Slattery, C F, Toombs, J, Svensson, J, Johansson, P, Fox, N C, Zetterberg, H, Mills, K, Schott, J M
Publicado no Transl Psychiatry (2016)

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Por Salloway, S, Sperling, R, Gilman, S, Fox, N C., Blennow, K, Raskind, M, Sabbagh, M, Honig, L S., Doody, R, van Dyck, C H., Mulnard, R, Barakos, J, Gregg, K M., Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M
Publicado em 2009

The heritability and genetics of frontotemporal lobar degeneration

Por Rohrer, J D., Guerreiro, R, Vandrovcova, J, Uphill, J, Reiman, D, Beck, J, Isaacs, A M., Authier, A, Ferrari, R, Fox, N C., Mackenzie, I R.A., Warren, J D., de Silva, R, Holton, J, Revesz, T, Hardy, J, Mead, S, Rossor, M N.
Publicado em 2009

Impact of APOE4-CSF Aβ interaction on hippocampal volume loss over 1 year in MCI

Por Chiang, G.C., Insel, P.S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S.T., Thompson, P.M., Reiman, E.M., Jack, C.R., Fox, N.C., Jagust, W.J., Harvey, D.J., Beckett, L.A., Gamst, A., Aisen, P.S., Petersen, R.C., Weiner, M.W.
Publicado em 2011

Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series

Por Koriath, C., Kenny, J., Adamson, G., Druyeh, R., Taylor, W., Beck, J., Quinn, L., Mok, T. H., Dimitriadis, A., Norsworthy, P., Bass, N., Carter, J., Walker, Z., Kipps, C., Coulthard, E., Polke, J. M., Bernal-Quiros, M., Denning, N., Thomas, R., Raybould, R., Williams, J., Mummery, C. J., Wild, E. J., Houlden, H., Tabrizi, S. J., Rossor, M. N., Hummerich, H., Warren, J. D., Rowe, J. B., Rohrer, J. D., Schott, J. M., Fox, N. C., Collinge, J., Mead, S.
Publicado no Mol Psychiatry (2018)